CL2025003367A1 - Nanosupensiones de corticosteroides y sus usos - Google Patents

Nanosupensiones de corticosteroides y sus usos

Info

Publication number
CL2025003367A1
CL2025003367A1 CL2025003367A CL2025003367A CL2025003367A1 CL 2025003367 A1 CL2025003367 A1 CL 2025003367A1 CL 2025003367 A CL2025003367 A CL 2025003367A CL 2025003367 A CL2025003367 A CL 2025003367A CL 2025003367 A1 CL2025003367 A1 CL 2025003367A1
Authority
CL
Chile
Prior art keywords
nanosuppressions
corticosteroid
treat
enthesitis
tenosynovitis
Prior art date
Application number
CL2025003367A
Other languages
English (en)
Inventor
Wang Laurene
J Nunez Derek
B Cook Jason
W-c LIAW Wayne
Original Assignee
Aimmax Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimmax Therapeutics Inc filed Critical Aimmax Therapeutics Inc
Publication of CL2025003367A1 publication Critical patent/CL2025003367A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen formulaciones de suspensión de nanopartículas de propionato de clobetasol. Las suspensiones se pueden utilizar terapéuticamente para tratar quemaduras cutáneas y oculares; para mejorar la cicatrización de heridas; para prevenir o reducir cicatrices hipertróficas/queloides; para tratar rinitis alérgica/sinusitis, asma, trastornos del oído interno, que incluyen pérdida de la audición, tinnitus o vértigo, tenosinovitis, tendinitis, entesitis o artritis.
CL2025003367A 2023-05-01 2025-10-30 Nanosupensiones de corticosteroides y sus usos CL2025003367A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363463113P 2023-05-01 2023-05-01

Publications (1)

Publication Number Publication Date
CL2025003367A1 true CL2025003367A1 (es) 2026-03-06

Family

ID=93333275

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025003367A CL2025003367A1 (es) 2023-05-01 2025-10-30 Nanosupensiones de corticosteroides y sus usos

Country Status (11)

Country Link
EP (1) EP4704852A2 (es)
KR (1) KR20260005253A (es)
CN (1) CN121038796A (es)
AU (1) AU2024265712A1 (es)
CL (1) CL2025003367A1 (es)
CO (1) CO2025015291A2 (es)
IL (1) IL324263A (es)
JO (1) JOP20250270A1 (es)
MX (1) MX2025013065A (es)
TW (1) TW202448423A (es)
WO (1) WO2024228993A2 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
HUE055016T2 (hu) * 2017-06-23 2021-10-28 Salvat Lab Sa Olaj-a-vízben nanoemulziós klobetazol készítmény

Also Published As

Publication number Publication date
CO2025015291A2 (es) 2025-11-19
KR20260005253A (ko) 2026-01-09
EP4704852A2 (en) 2026-03-11
MX2025013065A (es) 2025-12-01
WO2024228993A2 (en) 2024-11-07
JOP20250270A1 (ar) 2025-10-29
AU2024265712A1 (en) 2025-11-13
CN121038796A (zh) 2025-11-28
IL324263A (en) 2025-12-01
WO2024228993A3 (en) 2025-03-20
TW202448423A (zh) 2024-12-16

Similar Documents

Publication Publication Date Title
CL2020002573A1 (es) Inhibidores atf6 y sus usos.
ECSP22051247A (es) Fluoroalquil-oxadiazoles y sus usos
AR034619A1 (es) Formulaciones de olopatadine para administracion topica
MX388437B (es) Composiciones de cannabidiol y usos de las mismas.
BR112022019794A2 (pt) Derivados de pirrolo[2,3-f]indazol e 2,4,5,10-tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11- penteno como moduladores da alfa-1-antitripsina para tratamento da deficiência de alfa-1-antitripsina (aatd)
CL2022003348A1 (es) Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios
UY4906S (es) Par de audífonos
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
MX2024010236A (es) Akkermansia para prevenir y/o tratar trastornos de desregulación de la recompensa.
CO2025015291A2 (es) Nanosupensiones de corticosteroides y sus usos
MX2024006768A (es) Compuestos y usos de los mismos.
BR112018077060A2 (pt) composição antimicrobiana e métodos que empregam a mesma
UY39482A (es) Compuestos moduladores del cftr, composiciones y usos de estos
CL2020003458S1 (es) Auriculares.
BR112021019854A2 (pt) Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares
BR112022017193A2 (pt) Composições para interromper a formação de biofilme e para tratar distúrbios relacionados a biofilme
MX420447B (es) Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona
BR112012007091A2 (pt) composições de olopatadina e seus usos
Karkos et al. Evidence-based applications of mitomycin C in the nose
ECSP22008993A (es) Derivados de alcohol como abridores del canal de potasio kv7
EP4090420A4 (en) PHOTOTHERAPEUTIC TREATMENT OF SKIN DISEASES
CO2023014093A2 (es) Formulaciones de l-asparaginasa
CO2023003129A2 (es) Vacunas contra infecciones por sars-cov-2
MX2024007944A (es) Derivados de 4-fenil-tetrahidropiridina para el tratamiento de enfermedades auditivas.
CA3135658A1 (en) Mesenchymal stem cells for treatment of skin disorders and skin problems